Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Completely randomized design

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Completely randomized design. Displaying page 1 of 1.
    EudraCT Number: 2011-004257-29 Sponsor Protocol Number: 11-12 Start Date*: 2013-05-03
    Sponsor Name: All Ireland Cooperative Oncology Research Group ( ICORG)
    Full Title: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma
    Medical condition: High-risk resected melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10025651 Malignant melanoma excision LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-002644-21 Sponsor Protocol Number: NVALT-8A Start Date*: 2009-07-13
    Sponsor Name:UMCG
    Full Title: A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low-risk for recurrence: NVALT-8A
    Medical condition: This is a randomized multicenter phase III study. Patient with a low SUV of the primary tumor prior to surgery will be randomised to four cycles of cisplatin-based chemotherapy or observation in a ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000043-78 Sponsor Protocol Number: CA184-205 Start Date*: 2014-04-30
    Sponsor Name:University of Essen
    Full Title: Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus ob...
    Medical condition: completely resected Merkel cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000279-34 Sponsor Protocol Number: UOB2886 Start Date*: 2018-04-20
    Sponsor Name:Research, Enterprise & Development (RED), University of Bristol
    Full Title: Mistletoe And Breast Cancer (MAB): A pilot study for a randomized double-blind controlled trial
    Medical condition: Breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-004196-37 Sponsor Protocol Number: PA02-124 1 RO1AT002146-01 Start Date*: 2006-09-22
    Sponsor Name:University of Birmingham, Research & Enterprise Services [...]
    1. University of Birmingham, Research & Enterprise Services
    2. Heart of England NHS Foundation Trust Birmingham Heartlands Hospital
    Full Title: Taurine and Painful Diabetic Neuropathy
    Medical condition: Diabetic painful peripheral neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004116-38 Sponsor Protocol Number: RIFUND-MS Start Date*: 2015-12-18
    Sponsor Name:Department of Clinical Sciences, Danderyd Hospital
    Full Title: RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis – RIFUND-MS A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis Ob...
    Medical condition: Patients with multiple sclerosis (MS) or patients presenting with symptoms highly suspicious of MS while not completely fulfilling diagnostic criteria, 18 - 50 years of age and no more than 10 year...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004824-77 Sponsor Protocol Number: 27UCS2015 Start Date*: 2016-06-23
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial design biomarker tertiary prevention trial of low-dose aspirin and metformin in resected stage I-III colorectal ...
    Medical condition: Surgical resected colorectal cancer (stage I-III)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001167-12 Sponsor Protocol Number: IMMUNED Start Date*: 2015-05-21
    Sponsor Name:University of Essen
    Full Title: A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanom...
    Medical condition: Stage IV melanoma with no evidence of disease after surgery or radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001012-35 Sponsor Protocol Number: G200802 Start Date*: 2015-10-06
    Sponsor Name:GTx, Inc.
    Full Title: A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in...
    Medical condition: Estrogen Receptor Positive and Androgen Receptor Positive Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003187-44 Sponsor Protocol Number: UC-0140/1208 Start Date*: 2012-09-25
    Sponsor Name:UNICANCER
    Full Title: Randomized, double-blind, multicentric phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2- primary breast ...
    Medical condition: women with poor prognosis, ER+ and HER2- primary breast cancer who remain free of disease after receiving 3 years of adjuvant hormone therapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 13:32:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA